共 49 条
- [21] Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trialJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)Sato, YasuyoshiMatsushita, HirokazuMori, KazuhikoKakimi, KazuhiroSeto, Yasuyuki
- [22] A Comparison of Stereotactic Radiation Therapy in Elderly Patients with Central or Peripheral Stage I-II (T1-3 N0 M0) Non-Small Cell Lung CancerCANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1557 - 1570Ji, XiaoqinShi, XuebingHu, JunJiang, WanrongZhou, BinZhou, HoulongYuan, XiLi, YikunHuang, HuaWang, JiashengDing, WeiWang, YongSun, Xiangdong
- [23] The triplet gemcitabine, epirubicin, and docetaxel as primary systemic chemotherapy in primary breast cancer T2-4, N0-2, M0: final primary endpoint analysis of a multicentric phase I/II trial.BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S56 - S56Schneeweiss, AGeberth, MSinn, HPKrauss, KBeldermann, FWagner, Uvon Fournier, DHamerla, RMarseille, ABauknecht, TWallwiener, DBastert, GHuober, J
- [25] Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy prior to radical prostatectomy for patients with high risk localized prostate cancer: Pathologic outcomes and 3-year follow-up analysesJOURNAL OF UROLOGY, 2007, 177 (04): : 377 - 377Gleave, Martin E.Chi, KimChin, Joseph L.Winquist, EricKlotz, Laurence H.Berry, ScottRuether, DeanTrachtenberg, JohnMoore, Malcolm
- [26] PHASE III MULTICENTER, PROSPECTIVE, CONTROLLED, RANDOMIZED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TREATMENT OF RECTAL CANCER T2-T3S (SUPERFICIAL) N0, M0 WITH PREOPERATIVE CHEMORADIOTHERAPY AND TRANSANAL ENDOSCOPIC MICROSURGERY VERSUS TOTAL MESORECTAL EXCISION. PRELIMINARY RESULTSDISEASES OF THE COLON & RECTUM, 2015, 58 (05) : E323 - E324Serra-Aracil, X.Mora, L.Pericay, C.Delgado, S.Targarona, E.Vallribera, F.Golda, T.Reina, A.
- [27] Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivinCANCER RESEARCH, 2016, 76Tryggestad, Anne Merete Aa.Axcrona, KarolBigalke, IrisInderberg-Suso, Else M.Skorstad, GjertrudAxcrona, UlrikaAamdal, SteinarGaudernack, GustavSchendel, DoloresLilleby, WolfgangDueland, SveinKvalheim, Gunnar
- [28] A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-Small Cell Lung Cancer; Japan Clinical Oncology Group (JCOG0403); Long Term Follow-up ResultsINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S9 - S9Nagata, Y.Hiraoka, M.Shibata, T.Onishi, H.Kokubo, M.Karasawa, K.Shioyama, Y.Onimaru, R.Kunieda, E.Ishikura, S.
- [29] Results of AFU-GETUG-20: A randomised phase 3 trial of adjuvant androgen deprivation therapy with leuprorelin acetate after radical prostatectomy in patients with high-risk localized prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)Rozet, FrancoisRuffion, AlainSoulie, MichelRobert Sr, GregoireWalz, Jochende la Taille, AlexandrePfister, ChristianMathieu, RomainDescazeaud, AurelienLatorzeff, IgorBrureau, LaurentColombel, MarcRoupret, MorganRoca, LiseLemercier, PabloFizazi, KarimCuline, Stephane
- [30] Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Eggermont, A. M.Suciu, S.Rutkowski, P.Marsden, J.Testori, A.Corrie, P.Aamdal, S.Ascierto, P. A.Patel, P.Spatz, A.